Research Article

Vitamin E Loaded Naringenin Nanoemulsion via Intranasal Delivery for the Management of Oxidative Stress in a 6-OHDA Parkinson’s Disease Model

Table 5

Pharmacokinetic parameters of the NRG solution (i.v. and i.n.) and NE formulation after i.n. administration.

FormulationOrgan/Tissue (ng/ml) (h) (H) (ng/mlh) (ng/mlh)

NRG sol (i.n.)Brain870.77 ± 5.426.84 ± 0.20.1 ± 0.0033352.86 ± 8.95813.18 ± 9.2
Blood775.44 ± 2.514.63 ± 0.40.14 ± 0.041919.734 ± 6.72554.17 ± 8.1

NRG NE (i.v.)Brain381.67 ± 3.117.44 ± 0. 80.09 ± 0.0031599.36 ± 4.53118.87 ± 11.2
Blood2502.74 ± 4.20.53.13 ± 0.70.22 ± 0.0077533.91 ± 4.59582.21 ± 7.8

NRG NE (i.n.)Brain1148.64 ± 3.3213.38 ± 1.10.05 ± 0.0015345.13 ± 7.513543.23 ± 6.9
Blood794.33 ± 7.1210.4 ± 0.30.06 ± 0.023777.63 ± 5.38690.07 ± 8.5

Pharmacokinetic parameters results clearly indicated that the NRG concentration is significantly higher in optimized formulation administered via i.n. (p<0.05) than that of administration of optimized formulation via i.v. and NRG solution via i.v. route.